Navigation Links
D-Pharm Secures Funding From Israel's Chief Scientist's Office
Date:4/6/2008

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its commitment to match expenditures on four of D-Pharm's R&D programs with a total grant of up to NIS 11 million (over $3 million).

Alex Kozak, PhD, CEO and President of D-Pharm, said "We are grateful to the CSO for this vote of confidence and its firm support over the years, from the time of the company's inception as a technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis".

D-Pharm's drug-development programs emerged from the company's unique platform technology of lipid-like medicine. The CSO grant supports four major company developments: GMP production of DP-b99 in-house, IND preparations and initiation of a pivotal Phase III trial in stroke patients; a Phase II migraine study of DP-VPA in Israeli medical centers; and two preclinical programs, DP-460 for Alzheimer's disease and LipidoMimetix for cancer.

The Chief Scientist's Office has supported D-Pharm since its establishment, providing grants of about $18 million, excluding this latest announcement.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. D-Pharm recently received Israeli health ministry approval to commence a Phase II study of DP-VPA in migraine patients. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer. D-Pharm recently completed a $5 million rights issue to ensure timely commencement of the pivotal Phase III study of DP-b99, in acute stroke patients, as planned.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com


'/>"/>
SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. Aerovance Secures $20 Million in Debt Financing
3. Amarin Secures Global Intellectual Property Rights for Lipid Programs
4. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Taligen Therapeutics Secures Series B Financing
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Dendreon Secures $130 Million Committed Equity Financing Facility
9. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology Lab ... initiatives for potential stem cell protocol management for 2016 – 2020. , In ... to establish a working agenda and foster initiatives to promote stem cell research and ...
(Date:4/27/2016)... India , April 27, 2016 ... market research report with specific focus on US, ... Japan , to the healthcare business ... research library. Complete report on the ... 11 companies and supported with 282 tables and ...
(Date:4/26/2016)... City, CA (PRWEB) , ... April 26, 2016 ... ... for healthcare, today announced that Ardy Arianpour has joined the company as Chief ... years of experience bringing innovative genomic technologies to market, was most recently Chief ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, a ... technology innovation for its Volume Pattern Generator (VPG) line of lithography systems. The ... photomasks as well as a solution for mid volume direct write lithography applications. ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
(Date:3/9/2016)... Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> DERMALOG, the biometrics ...
Breaking Biology News(10 mins):